68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Christian SchmidkonzMichael CordesTheresa Ida GoetzOlaf PranteTorsten KuwertPhilipp RittMichael UderBernd WullichPeter GoebellTobias BäuerlePublished in: Annals of nuclear medicine (2019)
Our results suggest that 68Ga-PSMA-11 PET/CT might be a valuable tool for the detection and follow-up of bone metastases in patients with metastasized prostate cancer. 68Ga-PSMA-11 PET-derived quantitative volumetric parameters demonstrated a highly significant correlation with changes of serum-PSA levels during the course of therapy. No such correlation could be determined for bone density measurements of metastatic bone lesions. Compared to the fully diagnostic CT scan, a significantly higher proportion of bone metastases was detected on 68Ga-PSMA-11 PET.
Keyphrases
- pet ct
- prostate cancer
- positron emission tomography
- radical prostatectomy
- computed tomography
- end stage renal disease
- bone mineral density
- ejection fraction
- newly diagnosed
- small cell lung cancer
- high resolution
- machine learning
- chronic kidney disease
- squamous cell carcinoma
- bone loss
- prognostic factors
- soft tissue
- deep learning
- magnetic resonance imaging
- bone regeneration
- stem cells
- postmenopausal women
- image quality
- dual energy
- label free
- contrast enhanced
- real time pcr
- patient reported